Medicine information BORTEZOMIB ACCORD 3.5mg powder for solution for injection

Product code:
W65669001
Quantity:
1
Indicated for:
multiple myeloma
Route of administration:
injectable
Substance:
bortezomib (proteasome inhibitor)
ATC
L01XG01 — Antineoplastic and immunomodulating agents | Other antineoplastic agents | Proteasome inhibitors
Bortezomib is a medication used for the treatment of multiple myeloma and mantle cell lymphoma. It is a proteasome inhibitor that interferes with essential cellular processes in cancer cells, leading to their death.

The medication is administered via subcutaneous or intravenous injection, usually in treatment cycles, as directed by a doctor. The dosage and duration of treatment are adjusted based on the patient's condition and response to therapy.

Common side effects include fatigue, nausea, diarrhea, peripheral neuropathy, and decreased blood cell counts. In rare cases, more severe adverse effects such as heart failure or pulmonary toxicity may occur.

Bortezomib is not recommended for pregnant or breastfeeding women, as it may affect fetal development. Patients should inform their doctor about all medications they are taking to avoid drug interactions.

General data about BORTEZOMIB ACCORD 3.5mg

Substance:
bortezomib
Date of latest medicines list:
01-10-2026
Product code:
W65669001
Strength:
3.5mg
Pharmaceutical form:
powder for solution for injection
Quantity:
1
Product type:
Generic medicine
Price:
1527.69 RON
Prescription status:
P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.

Marketing authorisation

Manufacturer:
ACCORD HEALTHCARE LTD. - MAREA BRITANIE
Holder:
ACCORD HEALTHCARE S.L.U. - SPANIA
Number:
1019/2015/01
Shelf life:
3 years

Pharmaceutical forms available for bortezomib

Strengths available for bortezomib

  • 1mg
  • 2.5mg
  • 2.5mg/ml
  • 25mg/ml
  • 3.5mg

Official documents

The SmPC text is not displayed because a match to this medicine, strength and pharmaceutical form has not been confirmed.

The correspondence between the document and the displayed text is unconfirmed.

Source institution
EMA
Document language
English
Source record: first published
27/07/2015
Source record: last updated
25/03/2026

Warnings:

Fertility warning

This medicine may affect fertility.

Cytotoxic / special handling

Handle with special care.

Contraception required

Effective contraception is required during treatment.

Contraindicated during breastfeeding

Do not use this medicine while breastfeeding.

Contraindicated during pregnancy

Do not use this medicine during pregnancy.

Hepatotoxicity

This medicine may affect the liver.

Major drug interactions

This medicine may have important interactions with other medicines.

Myelosuppression / agranulocytosis

This medicine may lower blood cell counts.

Additional monitoring

This medicine is subject to additional monitoring.

Requires periodic laboratory tests

Periodic laboratory tests may be required during treatment.

Neuropathy / neurotoxicity

This medicine may affect the nerves or nervous system.

Severe skin reactions

Stop taking the medicine and seek urgent medical help if a severe rash occurs.

Reimbursement lists for BORTEZOMIB ACCORD 3.5mg Accord

NHP 3 (C2) - NHP oncology

Price
1527.69 RON
Copayment
932.21 RON
Patient payment
595.48 RON